Status:
COMPLETED
Perioperative Use of Atosiban for Ultrasound-indicated Cerclage to Reduce Spontaneous Preterm Birth(sPTB)
Lead Sponsor:
Children's Hospital of Chongqing Medical University
Collaborating Sponsors:
First Affiliated Hospital of Chongqing Medical University
Conditions:
Cervical Cerclage
Premature Birth
Eligibility:
FEMALE
Phase:
NA
Brief Summary
After ultrasound-indicated cerclage, some pregnant women still experience sPTB, and there is controversy regarding the use of tocolytic agents during the perioperative period to reduce the incidence o...
Eligibility Criteria
Inclusion
- (i) Viable singleton gestation between 14 0/7 and 23 6/7 weeks of gestation.
- (ii) Previous history of miscarriage or preterm labor in mid-pregnancy.
- (iii) Transvaginal ultrasound examination showed that the cervix is 25mm or less at gestations less than 24 weeks.
Exclusion
- (i) Women with uterine contractions.
- (ii) Vaginal bleeding.
- (iii) Symptoms of chorioamnionitis.
- (iv) Medically indicated PTB (severe preeclampsia, placental abruption, preterm premature rupture of membranes).
- (v) Major structural or chromosomal abnormalities.
- (vi) Contraindication to atosiban.
- (vii) Had received atosiban or any tocolytic agents within 7 days before their presentation.
Key Trial Info
Start Date :
January 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 12 2024
Estimated Enrollment :
334 Patients enrolled
Trial Details
Trial ID
NCT06537778
Start Date
January 3 2018
End Date
April 12 2024
Last Update
May 22 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Women and Children's Hospital of Chongqing Medical University
Chongqing, Chognqing, China, 400016
2
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400000